Apcin-A

Overview

Apcin -A is a small molecule inhibitor that selectively targets the cell division cycle protein Cdc20 and is a derivative of Apcin ( HY-110287 ). Apcin -A competitively binds to the D-box binding pocket of Cdc20 and inhibits substrate ubiquitination mediated by the anaphase promoting complex APC/C -Cdc20. Apcin -A also blocks the binding of Cdc20 to substrates (such as securin and cyclin B1), inhibiting anaphase initiation and cell cycle exit. Apcin -A can promote or prolong mitotic slippage in coordination with p31 comet under conditions of high spindle assembly checkpoint (SAC) activity. Apcin -A can be used to develop anti-mitotic drugs and overcome tumor chemotherapy resistance. Apcin -A can be used to synthesize PROTAC CP5V ( HY-130257 )[1][2][3].

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > PROTAC | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > APC | Products > Signaling Pathways > Ligands for Target Protein for PROTAC

Product Information

• Catalog No.: HY-130841
• CAS No.: 1683617-62-0
• Molecular Formula: C10H14Cl3N5O2
• Molecular Weight: 342.61
• Purity: 98.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (7.30 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source